Patient Characteristics and General Practitioners’ Advice to Stop Statins in Oldest-Old Patients: a Survey Study Across 30 Countries

Archive ouverte

van der Ploeg, Milly | Streit, Sven | Achterberg, Wilco | Beers, Erna | Bohnen, Arthur | Burman, Robert | Collins, Claire | Franco, Fabio | Gerasimovska-Kitanovska, Biljana | Gintere, Sandra | Gomez Bravo, Raquel | Hoffmann, Kathryn | Iftode, Claudia | Peštić, Sanda Kreitmayer | Koskela, Tuomas | Kurpas, Donata | Maisonneuve, Hubert | Mallen, Christan | Merlo, Christoph | Mueller, Yolanda | Muth, Christiane | Petrazzuoli, Ferdinando | Rodondi, Nicolas | Rosemann, Thomas | Sattler, Martin | Schermer, Tjard | Šter, Marija Petek | Švadlenková, Zuzana | Tatsioni, Athina | Thulesius, Hans | Tkachenko, Victoria | Torzsa, Péter | Tsopra, Rosy | Tuz, Canan | Vaes, Bert | Viegas, Rita | Vinker, Shlomo | Wallis, Katharine | Zeller, Andreas | Gussekloo, Jacobijn | Poortvliet, Rosalinde

Edité par CCSD ; Springer Verlag -

International audience. BackgroundStatins are widely used to prevent cardiovascular disease (CVD). With advancing age, the risks of statins might outweigh the potential benefits. It is unclear which factors influence general practitioners’ (GPs) advice to stop statins in oldest-old patients.ObjectiveTo investigate the influence of a history of CVD, statin-related side effects, frailty and short life expectancy, on GPs’ advice to stop statins in oldest-old patients.DesignWe invited GPs to participate in this case-based survey. GPs were presented with 8 case vignettes describing patients > 80 years using a statin, and asked whether they would advise stopping statin treatment.Main MeasuresCases varied in history of CVD, statin-related side effects and frailty, with and without shortened life expectancy (< 1 year) in the context of metastatic, non-curable cancer. Odds ratios adjusted for GP characteristics (ORadj) were calculated for GPs’ advice to stop.Key ResultsTwo thousand two hundred fifty GPs from 30 countries participated (median response rate 36%). Overall, GPs advised stopping statin treatment in 46% (95%CI 45–47) of the case vignettes; with shortened life expectancy, this proportion increased to 90% (95CI% 89–90). Advice to stop was more frequent in case vignettes without CVD compared to those with CVD (ORadj 13.8, 95%CI 12.6–15.1), with side effects compared to without ORadj 1.62 (95%CI 1.5–1.7) and with frailty (ORadj 4.1, 95%CI 3.8–4.4) compared to without. Shortened life expectancy increased advice to stop (ORadj 50.7, 95%CI 45.5–56.4) and was the strongest predictor for GP advice to stop, ranging across countries from 30% (95%CI 19–42) to 98% (95% CI 96–99).ConclusionsThe absence of CVD, the presence of statin-related side effects, and frailty were all independently associated with GPs’ advice to stop statins in patients aged > 80 years. Overall, and within all countries, cancer-related short life expectancy was the strongest independent predictor of GPs’ advice to stop statins.

Suggestions

Du même auteur

Burden of cardiovascular disease across 29 countries and GPs’ decision to treat hypertension in oldest-old

Archive ouverte | Streit, Sven | CCSD

International audience. We previously found large variations in general practitioner (GP) hypertension treatment probability in oldest-old (>80 years) between countries. We wanted to explore whether differences in c...

Variation in GP decisions on antihypertensive treatment in oldest-old and frail individuals across 29 countries

Archive ouverte | Streit, Sven | CCSD

International audience. In oldest-old patients (>80), few trials showed efficacy of treating hypertension and they included mostly the healthiest elderly. The resulting lack of knowledge has led to inconsistent guid...

General practitioners’ deprescribing decisions in older adults with polypharmacy: a case vignette study in 31 countries

Archive ouverte | Jungo, Katharina, Tabea | CCSD

International audience. Background: General practitioners (GPs) should regularly review patients' medications and, if necessary, deprescribe, as inappropriate polypharmacy may harm patients' health. However, depresc...

Chargement des enrichissements...